FDA Clearance Tracker · P160048-S006
Eversense Continuous Glucose Monitoring System
Last checked: Nov 20, 2026Latest source record: Jun 6, 2019 (this decision)Source: openFDAMethods & limitations
Decided
Jun 6, 2019
Approved
Time to decision
192 days
Received Nov 26, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P160048-S006
- Device name
- Eversense Continuous Glucose Monitoring System
- Applicant
- Senseonics, Incorporated
- Applicant location
- Germantown, MD
- Received
- Nov 26, 2018
- Decided
- Jun 6, 2019
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P160048
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for the Eversense CGM System. The device is indicated for continually measuring glucose levels in adults (age 18 and older) with diabetes for up to 90 days. The system is indicated for use to replace fingerstick blood glucose measurements for diabetes treatment decisions.The system is intended to:1) Provide real-time glucose readings;2) Provide glucose trend information; and3) Provide alerts for the detection and prediction of episodes of low blood glucose (hypoglycemia) and high blood glucose (hyperglycemia).The system is a prescription device. Historical data from the system can be interpreted to aid in providing therapy adjustments. These adjustments should be based on patterns seen over time. The system is intended for single patient use.
Source documents
Other decisions for Senseonics, Incorporated
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K241335 · Decided Sep 16, 2024 · 126 days after receipt
Device type: Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate (SBA) · Laboratory Medicine & Pathology
4 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.